MindRank Pharma to Showcase AI-Driven Drug Discovery Breakthroughs at LSX World Congress 2025
MindRank
AI Drug Developer
MindRank Chief Commercial Officer Lin Jian will attend9Month16Day-17Day in Boston, USA2025 LSXWorld Congress, and local time16Day (11:25 - 11:50 ET) delivered a speech titled "AIDesign for Oral AdministrationGLP-1RASmall Molecules:First-in-class IIbClinical Data and Translational Insights." Looking forward to exchanging insights with industry experts, scholars, and partners offline at that time.
AboutLSXWorld Congress
LSXThe World Congress is an international top-tier event in the biotechnology, pharmaceuticals, health, and other technology sectors. The conference focuses on promoting cooperation, strategic exchange, and investment in the global healthcare industry. Through large-scale conferences, forums, seminars, and other formats, it brings together executives from multinational pharmaceutical companies, representatives of research institutions, investors, and other professionals to jointly discuss cutting-edge technologies, innovative trends, and industry challenges, supporting future drug development.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby making more diseases treatable and restoring health to more lives.
The company owns a self-developed, internationally leading industrial-grade one-stop AI-driven innovative drug research and development platform, including the knowledge graph-based data mining platform PharmKG™, the protein dynamic simulation and structure prediction platform Molecule Dance™, and the one-stop AI drug design platform Molecule Pro™.
MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018-2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Enterprise List as one of "China's Most Socially Impactful Startups."
MindRank's Self-Developed One-Stop AI Pharmaceutical Platform
Related Reading:
MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region
For more information, please visit the website: www.mindrank.ai
Contact: bd@mindrank.ai pr@mindrank.ai
Other: info@mindrank.ai